10X Fund, L.P.
Known title: 10% OwnerCIK: 0001453356
Associated companies
Transaction History
| GALT | ▼ Sell | Open Market | 30,681 | $204K | 12/16/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 120,000 | $688K | 12/3/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 30,000 | $164K | 12/2/2025 | View on chart |
| GALT | ▼ Sell | Other | 24,000 | — | 11/24/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 40,000 | $210K | 11/11/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 20,000 | $99K | 10/22/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 30,000 | $148K | 10/22/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 10,000 | $21K | 7/22/2022 | View on chart |
| GALT | ▼ Sell | Open Market | 10,000 | $21K | 2/2/2022 | View on chart |
| GALT | ▼ Sell | Open Market | 10,000 | $21K | 1/11/2022 | View on chart |
| GALT | ▼ Sell | Open Market | 10,000 | $24K | 12/2/2021 | View on chart |
| GALT | ▼ Sell | Open Market | 10,000 | $32K | 11/1/2021 | View on chart |
| GALT | ▼ Sell | Open Market | 10,000 | $34K | 10/15/2021 | View on chart |
| GALT | ▼ Sell | Open Market | 10,000 | $36K | 10/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.